Notes

LSD1-Demethylated LINC01134 Confers Oxaliplatin Opposition by way of SP1-induced p62 Transcribing inside Hepatocellular Carcinoma.
In the breast cancer subgroup, HER2Ile655Val SNP was significantly associated with younger age women with breast cancer in the dominant model. In contrast, no association between the HER2 codon 655 SNP and age was found in control populations.

Our findings suggest that the Val allele in HER2 codon 655 SNP is strongly associated with breast cancer susceptibility in the young female population and is also significantly associated with younger age in women with breast cancer. HER2Ile655Val SNP might be a susceptibility factor that favours early-onset breast cancer.<br />.
.
Genetic polymorphisms can influence the chemotherapeutic response; however, previous studies have produced conflicting results, and have failed to identify the most relevant polymorphisms for predicting the response to treatment in patients with cancer. The present meta-analysis was conducted to determine the correlation between two polymorphisms (rs1045642 and rs1128503) in ATP-binding cassette transporter B subfamily member 1 (ABCB1), which is associated with multidrug resistance, and the survival of patients treated with taxane-containing chemotherapy.

Several databases, including PubMed and Embase, were used to retrieve articles evaluating the association between the ABCB1 rs1045642 and rs1128503 polymorphisms and survival, published prior to August 2019. The meta-analysis was conducted using R software to determine the pooled hazard ratio (HR) and 95% confidence intervals (95% CIs).

Fifteen studies involving 3320 patients were included in the meta-analysis. The effect of the rs1128503 polymorphism on progression-free survival remained significant in the heterozygote (HR 0.81; 95% CI 0.67-0.98) and homozygote (HR 0.71; 95% CI 0.58-0.88) models. The TT genotype rs1128503 was associated with better overall survival (HR 0.72; 95% CI 0.53-0.97).

Carriers of the rs1128503 T allele of ABCB1 showed a survival benefit after taxane-containing chemotherapy.
Carriers of the rs1128503 T allele of ABCB1 showed a survival benefit after taxane-containing chemotherapy.The advent of the electronic health record (EHR) raises many questions regarding its adoption and its added value for patients, clinicians and the entire healthcare system. Based on the results of a participatory project that brought together citizens and experts, we show that the EHR should be understood as a collective and evolving project serving public health objectives, and that both patients and healthcare professionals should contribute to its development. Therefore, this common project represents a significant opportunity to strengthen the patient-professionals partnership.Cognitive impairment can interfere with the fitness to drive. An increase in requests to assess this aspect is observed at Leenaards Memory Centre. Changes in the law could be an explanatory factor. The views formulated in 2019 are mainly unfavorable because all the patients present cognitive disorders, generally attributed to Alzheimer's disease or a related disorder, but never linked with aging only. Moreover, unfavorable views are frequently expressed before the age of 75. Therefore, each patient is unique, and each decision is based neither on the patient's age or his diagnosis, but rather on his cognitive profile. In this article we discuss the reasons for an unfavorable view and discuss them in the context of the tasks of our centre.Lacking diagnostic standards, the prevalence of Occupational Burnout (OB) remains uncertain. Unisanté aimed to evaluate its magnitude in its patients and to evaluate the medical practices related to OB in two of its departments, the Department of the Policlinics (DDP) and the Department of Occupational and Environmental Health (DSTE). An online survey has shown that 43/55 of the physicians participating in the survey have already diagnosed patients with OB in their practice. Two focus groups allowed to evaluate the interest and usefulness of a standardized diagnostic tool for physicians of the DDP and the DSTE. The tool turned out not to be appropriate in its present form, but this work allowed to sensitize physicians to OB and to clarify the recommendations for the screening and treatment of OB patients at Unisanté.In 2020, clinical studies have opened the way for several new treatment options in rheumatoid arthritis, psoriasis arthritis, spondylarthritis and lupus. However, this year was mainly characterized by the Covid-19 pandemic which had a substantial impact on rheumatology. The initial fear for immune-compromised patients undergoing more severe Covid-19 courses remained without evidence. The same was true for the hype of several rheumatic treatments such as Plaquenil or anti-IL-6 blockade which finally did not show efficacy in prospective trials for Covid-19 pneumonia. On the other side, notably the first confinement had a substantial negative impact on rheumatic patients. Our patients are still struggling with the consequences of prolonged immobilization, lack of physiotherapy, missing consultations and treatment adaption as well as social isolation and depression. Telemedicine and upcoming digital solutions compensated this gap at least partially. The post-Covid syndrome with persisting fibromyalgia-like symptoms potentially will join the spectrum of rheumatic disorders.In this review of the recent medical literature, we have identified 4 topics of interest for the readers of Revue Médicale Suisse. Use of antifibrotic drugs in interstitial lung diseases will soon be extended to a phenotype labeled « progressive fibrosing interstitial lung disease » (PF-ILD). While awaiting for evidence-based treatment, consensual recommendations for a treatment algorithm in pulmonary sarcoidosis has been published. New guidance for non-invasive ventilation in COPD and obesity-hypoventilation syndrome are available in Switzerland and are in line with international recommendations. Selleckchem ALK inhibitor New treatments targeting CFTR protein activity have become available and could become a therapeutic option for up to 85% of cystic fibrosis patients in Switzerland.The most frequent ocular manifestation of the SARS-CoV-2 is a conjunctivitis. It is found in 1-3% of patients and has unusually a benign course. In those patients but also in patients without ocular involvement, the virus can be detected by PCR in conjunctival swabs or in the tears. Whereas the presence of the virus in the conjunctiva is proven, its transmission through the conjunctiva is still discussed. Despite the poor level of evidence, the use of protective eyewear is recommended. Ocular thromboembolic events have been described in Covid-19. They can be found in the context of the Covid-related coagulopathy. A multidisciplinary approach should be provided in these cases. In the ICU, severe ocular complications might be indirectly related to Covid-19 in ventilated patients.
Website: https://www.selleckchem.com/ALK.html